COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Age & Gender

18 years ~ 99 years
Female

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Olivia Lara
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Other Cancers, Ovarian)

IRB Number

22-2935

ClinicalTrials.gov

NCT05445778

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.